Concomitant Radiotherapy and Daily Low-Dose Carboplatin in Locally Advanced, Unresectable Head and Neck Cancer Definitive results of a phase I-II study

References

• Marcia V A, Pajak T F, Kramer S, et al. Radiation Therapy Oncology Group (RTOG). Studies in head and neck cancer. Semin Oncol 1988; 15: 39–60
   PubMedGoogle Scholar
• Vokes E E, Weichselbaum R R. Concomitant chemoradiother-apy: rationale and clinical experience in patients with solid tumors. J. Clin Oncol 1990; 8: 911–34
   PubMed Web of Science ®Google Scholar
• Shigematsu Y, Sakai S, Fuchimata H. Recent trials in the treatment of maxillary sinus carcinoma with special reference to the chemical potentiation of radiation therapy. Acta Otolaryngol 1971; 71: 63–70
   PubMed Web of Science ®Google Scholar
• Stefani S, Eells R W, Abbate J. Hydroxyurea and radiotherapy in head and neck cancer. Radiology 1971; 101: 391–6
   PubMed Web of Science ®Google Scholar
• Lo T C, Wiley A L., Jr, Ansfield F J, et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 1976; 126: 229–35
   PubMed Web of Science ®Google Scholar
• Shanta V, Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. Clin Radiol 1980; 31: 617–20
   PubMed Web of Science ®Google Scholar
• Fu K K, Phillips T L, Silverberg I Y, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J. Clin Oncol 1987; 5: 1410–8
   PubMed Web of Science ®Google Scholar
• Weissberg J B, Son Y H, Papac R J, et al. Randomized clinical trial of mytomicin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989; 17: 3–9
   PubMed Web of Science ®Google Scholar
• Al Sarraf M, Pajak T F, Marcial V A, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study Cancer 1987; 59: 259–65
   PubMedGoogle Scholar
• Eisenberger M, Van Echo D, Aisner J. Carboplatin: the experience in head and neck cancer. Semin Oncol 1989; 16(Suppl 5)34–41
   PubMedGoogle Scholar
• Muggia F M. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 1989; 16(Suppl 5)7–13
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D. Carboplatin (NSC-241–240). An active platinum analog for the treatment of squamous cell carcinoma of the head and neck. J Clin Oncol 1986; 10: 1506–9
   Google Scholar
• Jacobs M C, Eisenberger M, Oh M C, et al. Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: a phase Til study. Int J Radiat Oncol Biol Phys 1989; 17: 361–3
   PubMed Web of Science ®Google Scholar
• Zamboglou N, Pape H, Schnabel T, et al. Kombinierte Ra-diotherapie mit Cis- oder Carboplatin bei fortgesschritten Kopf-Hals-Tumoren. Strahlenther Onkol 1989; 165: 647–51
   PubMedGoogle Scholar
• Volling P, Staar S, Achterrath W, Muller R P. Carboplatin plus radiation therapy in head and neck cancer. Semin Oncol 1991; 18(Suppl 2)17–22
   PubMedGoogle Scholar
• Douple E B, Richmond R C, O'Hara J A, Coughlin C T. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 1985; 12(Suppl A)111–24
   PubMed Web of Science ®Google Scholar
• Schwachofer J H, Crooijmans R P, Hoogenhout J, Kal H B, Theeuwes G M. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int J Radiat Oncol Biol Phys 1991; 20: 1235–41
   PubMed Web of Science ®Google Scholar
• Skov K, MacPhail S. Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys 1991; 20: 221–5
   PubMed Web of Science ®Google Scholar
• Bartelink H, Kallman R F, Rapacchietta D, Hart G A. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-ciamminedichloroplatinum (II) and irradiation. Radiother Oncol 1986; 6: 61–74
   PubMedGoogle Scholar
• Orecchia R, Urgesi A, Sacco M, et al. Daily low-dose carboplatin and standard radiotherapy in unresectable head and neck and lung cancer: a pilot study. Tumori 1991; 77: 423–5
   PubMedGoogle Scholar
• Orecchia R, Sannazzari G L, Airoldi M, Cortesina G. Daily carboplatin (CBDCA) and standard radiation therapy (RT) in inoperable head and neck cancer (HNC): a dose-finding study. Proc Am Soc Clin Oncol 1992; 11: 246
   Google Scholar
• Marcial V A, Pajak T F, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the RTOG Study 81–17. Cancer 1990; 66: 1861–8
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Rapacchietta D, Kallman R F. Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cis-diamminedichloroplatinum (II) in C3H/ KM mouse model system. Cancer Res 1988; 48: 3158–64
   PubMed Web of Science ®Google Scholar
• Brachman D, Haraf D, Weichselbaum R, et al. Granulocyte-colony stimulating factor (G-CSF) and concomitant accelerated chemoradiotherapy for advanced head and neck cancer: a dose-escalating study. Proc Am Soc Clin Oncol 1993; 12: 280
   Google Scholar
• Staar S, Volling P, Achterrath W, Muller R P. Carboplatin and simultaneous accelerated radiation in advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1992; 11: 246
   Google Scholar
• Schaake-Koning C, Van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524–30
   PubMed Web of Science ®Google Scholar